By Ian Walker

GlaxoSmithKline PLC said late Wednesday that it has stopped enrolling patients in a trial studying a combination drug therapy using feladilimab in cancer patients.

The pharmaceutical giant said it has decided to stop enrolling patients in the Phase 2 Induce-3 trial following a recommendation by the independent data monitoring committee. It has also decided to stop the Induce-4 Phase 2 trial.

The Induce-3 trial was investigating feladilimab in combination with pembrolizumab compared with a placebo in combination with pembrolizumab in patients with PD-L1 positive recurrent locally advanced or metastatic head and neck squamous cell carcinoma.

The Induce-4 trial was studying feladilimab compared with a placebo in combination with pembrolizumab and chemotherapy.

Glaxo said the data taken so far will be used to assess the impact on the overall clinical development program for feladilimab.

Write to Ian Walker at ian.walker@wsj.com

(END) Dow Jones Newswires

04-15-21 0144ET